Cord blood moves differently from almost everything else a clinic sends abroad. The unit is irreplaceable, the temperature window has no tolerance, and in most of the Gulf the border itself is the hardest part of the route. This is written for the people who have to sign the release — bank directors, transplant coordinators, quality managers — and it sets out what the published standards expect of a courier, what the regional authorisation layer looks like, and where the gaps are.
What You Are Actually Moving
A cord blood unit is cryopreserved. It travels at or below −150 °C, which in practice means a vapour-phase liquid nitrogen dry shipper running near −196 °C. We use the MVE SC 4/3. It is DGR-exempt, it carries no free liquid, and it holds its charge for the length of an intercontinental routing with margin to spare.
That is a different operation from fresh product. Apheresis collections and marrow harvests travel at +2 °C to +8 °C in a validated isothermal container, and the clock is the constraint rather than the temperature. Fresh material is generally considered viable for up to 72 hours from collection, but the receiving transplant centre sets the limit for each case, and we plan the route to the window they give us. We carry both. The reason for separating them here is that the two jobs have almost nothing in common operationally, and a courier that only owns dry shippers cannot run the fresh side at all.
Worth saying plainly, because it is a common category error: unmodified haematopoietic stem cells and cord blood are not medicinal products. In the European framework they sit under Directive 2004/23/EC, which covers donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. Good Distribution Practice belongs to medicinal products under Directive 2001/83/EC. Advanced therapy medicinal products — gene therapies, somatic cell therapies, CAR-T — do cross back into the medicinal-product world. If a courier offers you a GDP-aligned cold chain for an unmodified cord blood unit, they have reached for the wrong framework.
The Authorisation Layer in the Gulf
This section is informational. Regulations change, and the position for any individual shipment has to be confirmed with the authority itself and with your own legal advisors before anything moves.
United Arab Emirates
Council of Ministers Decision No. 6 of 2020, the regulations governing cord blood and stem cell storage centres, came into effect in January 2022 and is administered by the Ministry of Health and Prevention. Under that framework the import and export of cord blood stem cells requires prior formal permission. The same regulations require banks collecting cord blood inside the UAE to hold their laboratory and storage facilities in-country and to post a guarantee bond of AED 10 million. In Abu Dhabi, cell lines that have not previously been imported attract an additional approval step through the emirate's own health research and technology committee.
Read commercially rather than legally, that permission requirement is the whole job. It is why cord blood work in the region is coordination work before it is transport work.
Saudi Arabia
The Saudi Food and Drug Authority requires an importation licence before minimally manipulated biological products intended for human application may be brought into the Kingdom. Cell therapies that have been more than minimally manipulated are handled under the SFDA's advanced therapy guidelines instead, which is a different and longer path.
Oman
We could not find an authoritative public source setting out a dedicated Omani import and export regime for stem cells, so we are not going to describe one. What we can say is operational rather than regulatory: Embryo Links is a UAE company, we handle import and export of biological material through Oman, and Oman International Hospital is our partner clinic there. Anything beyond that should be confirmed directly with the Ministry of Health before a shipment is planned.
What the Published Standards Expect of a Courier
Three documents matter here, and none of them are ours.
The WMDA Guidelines for couriers and the transportation of cellular therapy products, second edition, were approved in April 2026. They are written for couriers specifically, which makes them the most directly applicable document this business has. FACT-JACIE's International Standards for Hematopoietic Cellular Therapy, now in their ninth edition, draw a distinction that is worth borrowing: shipping is when a product is handed to a carrier, and transport is when the product never leaves the control of trained personnel. NetCord-FACT covers cord blood specifically and expects continuous temperature monitoring as part of the shipping kit.
Read together, they describe a hand-carried, continuously monitored, continuously held operation. That is the model, and a courier should be able to tell you which of those documents they work to without looking it up.
Custody, Cabin and Screening
WMDA asks the courier to remain in continuous possession of the product at all times. Our courier takes the tank at the releasing facility and hands it over at the receiving one. There is no depot, no consolidation point, no transfer to a partner network in the middle.
On the aircraft, the guidance is more specific than most people expect. The product must never go into checked luggage, and it must not go inside the courier's own cabin bag either — it travels as its own item, positioned under the seat in front of the courier. The MVE SC 4/3 is carried that way on every leg. It cannot be checked in and it is never sent as cargo. Airline approval is obtained in writing, per booking, through the carrier's cargo or dangerous goods division rather than its general customer service line, because the general line will not give a usable answer.
On screening, WMDA asks couriers to make every possible effort to prevent the product passing through X-ray or other irradiation screening, and recommends a container label reading MEDICAL SPECIMEN – HANDLE WITH CARE DO NOT X-RAY. Our policy is firmer than that wording. Manual inspection is secured in advance with written support from both the releasing and receiving facilities, addressed to the security authority at each airport. If manual inspection is refused, the shipment does not proceed. We would rather hold a unit than guess about dose.
Temperature, and the Record of It
WMDA recommends data loggers for all cellular therapy product shipments, and for cryopreserved product asks the courier company to confirm before departure that a continuous temperature-monitoring device is installed, activated and working. NetCord-FACT treats continuous monitoring as part of the kit.
Our high-value and time-critical transports carry calibrated electronic loggers, and the receiving centre is given the full temperature history on arrival rather than a verbal assurance.
There is a reason this matters more here than in pharmaceutical logistics. A cryopreserved cellular product cannot be meaningfully assessed after a suspected excursion. A viability assay can look acceptable after damaging devitrification, because what has been lost is engraftment capacity rather than simple membrane integrity. A compromised unit looks identical to a sound one until it fails in the patient. There is no risk-based decision available at the far end. Prevention is the whole strategy, and the trace is how you demonstrate it held.
The Document Set
For a Gulf-bound cord blood move, the pack that actually travels usually comes to eight documents. The patient or donor agreement. A written agreement with the releasing facility, and another with the receiving one. A no X-ray letter from each end, each addressed to its own airport's security authority. A customs release letter for the destination airport. A copy of the export authorisation, naming the courier company. And the airline's written carry-on approval.
Clinics handle their own licensing and consent. We coordinate the courier side once that paperwork exists, and we prepare and chase the documents in that list that belong to the transport itself. Where a route has a stopover, every transit point has to be addressed in the documentation as well — a pack that covers origin and destination but ignores an intermediate stop is the most common way a well-planned move stalls.
How a Move Actually Runs
Enquiry and route assessment first, including which authorisations the corridor will need and roughly how long each takes. Then written agreements with both facilities, so everyone is working from the same scope. Then the authorisation applications, which the facility submits in its own name with the courier company named on the paperwork. Then the airline approval, in writing, per booking. Then collection, hand-carry, and release at the receiving end against documentation prepared in advance.
The authorisation step is the one that determines the calendar. Everything else can be compressed; a ministry cannot.
What You Are Buying
WMDA asks a commercial courier company to maintain a quality management system covering, at minimum, courier selection, training, incident management and documentation of corrective actions. That is a system, not a certificate, and it is the right thing to interrogate. Embryo Links runs ISO 9001 quality management, every member of staff holds UN3373 qualification, and we issue a written agreement per leg rather than relying on a standing arrangement. We have been moving biological material for more than twelve years, across more than thirty countries and more than 1,250 successful transfers to date.
We do not hold WMDA or FACT-JACIE courier accreditation, and we are not going to imply otherwise. What we can show you is the system behind the work, the logger trace from the last comparable route, and the agreement we would sign for yours.
Tell us the two facilities and the product type and we will come back with the authorisation path, the routing and a written quotation. We respond within the hour.
Chat on WhatsAppLast reviewed: 6 October 2026.